首都食品与医药
首都食品與醫藥
수도식품여의약
Capital Medicine
2015年
18期
32-33
,共2页
文拉法辛缓释片%西酞普兰片%抑郁症
文拉法辛緩釋片%西酞普蘭片%抑鬱癥
문랍법신완석편%서태보란편%억욱증
venlafaxine tablets%citalopram tablets%depression
目的:对文拉法辛缓释片与西酞普兰治疗抑郁症疾病进行研究,对比其疗效及安全性评价。方法将80例抑郁症患者随机分为文拉法辛组与西酞普兰组进行治疗,每组各40例,疗程均为8周。治疗前后分别采用抑郁自评量表(SDS)对患者进行测试,由心理导师进行分析,采用汉密尔顿抑郁量表(HAMD)及蒙哥马利抑郁量表(MADRS)对临床治疗效果进行评定,用副反应量表(TESS)来评定患者不良反应。结果在治疗第1周末和第2周末对比文拉法辛组与西酞普兰组汉密尔顿抑郁量表评分,发现文拉法辛组评分出现明显下降(P<0.05),表明文拉法辛缓释片起效快于西酞普兰片。两组在治疗8周后,文拉法辛组显效率约为93%,西酞普兰组显效率约为86%,表明文拉法辛缓释片在改善患者焦虑程度方面优于西酞普兰片。两组不良反应均较轻。结论文拉法辛缓释片在临床中见效快,安全性较好,能显著改善抑郁症患者焦虑躯体化症状,可作为临床中治疗抑郁症的首选药物。
目的:對文拉法辛緩釋片與西酞普蘭治療抑鬱癥疾病進行研究,對比其療效及安全性評價。方法將80例抑鬱癥患者隨機分為文拉法辛組與西酞普蘭組進行治療,每組各40例,療程均為8週。治療前後分彆採用抑鬱自評量錶(SDS)對患者進行測試,由心理導師進行分析,採用漢密爾頓抑鬱量錶(HAMD)及矇哥馬利抑鬱量錶(MADRS)對臨床治療效果進行評定,用副反應量錶(TESS)來評定患者不良反應。結果在治療第1週末和第2週末對比文拉法辛組與西酞普蘭組漢密爾頓抑鬱量錶評分,髮現文拉法辛組評分齣現明顯下降(P<0.05),錶明文拉法辛緩釋片起效快于西酞普蘭片。兩組在治療8週後,文拉法辛組顯效率約為93%,西酞普蘭組顯效率約為86%,錶明文拉法辛緩釋片在改善患者焦慮程度方麵優于西酞普蘭片。兩組不良反應均較輕。結論文拉法辛緩釋片在臨床中見效快,安全性較好,能顯著改善抑鬱癥患者焦慮軀體化癥狀,可作為臨床中治療抑鬱癥的首選藥物。
목적:대문랍법신완석편여서태보란치료억욱증질병진행연구,대비기료효급안전성평개。방법장80례억욱증환자수궤분위문랍법신조여서태보란조진행치료,매조각40례,료정균위8주。치료전후분별채용억욱자평량표(SDS)대환자진행측시,유심리도사진행분석,채용한밀이돈억욱량표(HAMD)급몽가마리억욱량표(MADRS)대림상치료효과진행평정,용부반응량표(TESS)래평정환자불량반응。결과재치료제1주말화제2주말대비문랍법신조여서태보란조한밀이돈억욱량표평분,발현문랍법신조평분출현명현하강(P<0.05),표명문랍법신완석편기효쾌우서태보란편。량조재치료8주후,문랍법신조현효솔약위93%,서태보란조현효솔약위86%,표명문랍법신완석편재개선환자초필정도방면우우서태보란편。량조불량반응균교경。결논문랍법신완석편재림상중견효쾌,안전성교호,능현저개선억욱증환자초필구체화증상,가작위림상중치료억욱증적수선약물。
Objective venlafaxine extended release tablets with citalopram treatment of depression disease study comparing the efficacy and safety evaluation.Methods 80 cases of depression were randomly divided into groups of venlafaxine and citalopram treatment group, 40 cases in each group, a course of eight weeks. Hamilton Depression Scale (HAMD) were assessed for clinical outcomes, with the side effects scale (TESS) to assess patients with adverse reactions.Results in the treatment of Objectivevenlafaxine extended release tablets with citalopram treatment of depression disease study comparing the efficacy and safety evaluation.Methods 80 cases of depression were randomly divided into groups of venlafaxine and citalopram treatment group, 40 cases in each group, a course of eight weeks. Hamilton Depression Scale (HAMD) were assessed for clinical outcomes, with the side effects scale (TESS) to assess patients with adverse reactions.Results in the treatment of <br> first and second weekend weekend venlafaxine group compared with citalopram Hamilton Depression Rating Scale and found that venlafaxine group score significant decline (P<0.05), showed that venlafaxine rapid onset of sustained-release tablets in citalopram tablets. After 8 weeks of treatment groups, venlafaxine group was about 93% efficiency, the efficiency of citalopram group was about 86%, indicating that venlafaxine extended release tablets in improving patient anxiety better than citalopram film. Two adverse reactions were mild.Conclusion venlafaxine extended release tablets in clinical quick, good safety, can significantly improve depression symptoms of anxiety and somatization, as a clinical drug of choice for treating depression.